Cancers 2013, 5(2), 569-590; doi:10.3390/cancers5020569

Immunotherapy and Immune Evasion in Prostate Cancer

1 Department of Oncology, Wayne State University, Detroit, MI 48201, USA 2 Department of Medicine, Wayne State University, Detroit, MI 48201, USA 3 Department of Immunology and Microbiology, Wayne State University, Detroit, MI 48201, USA
* Authors to whom correspondence should be addressed.
Received: 29 March 2013; in revised form: 16 April 2013 / Accepted: 8 May 2013 / Published: 24 May 2013
(This article belongs to the Special Issue Immune Responses to Human Prostate Cancer)
PDF Full-text Download PDF Full-Text [270 KB, uploaded 24 May 2013 16:34 CEST]
Abstract: Metastatic prostate cancer remains to this day a terminal disease. Prostatectomy and radiotherapy are effective for organ-confined diseases, but treatment for locally advanced and metastatic cancer remains challenging. Although advanced prostate cancers treated with androgen deprivation therapy achieves debulking of disease, responses are transient with subsequent development of castration-resistant and metastatic disease. Since prostate cancer is typically a slowly progressing disease, use of immune-based therapies offers an advantage to target advanced tumors and to induce antitumor immunity. This review will discuss the clinical merits of various vaccines and immunotherapies in castrate resistant prostate cancer and challenges to this evolving field of immune-based therapies.
Keywords: prostate cancer; immunotherapy; vaccine; castrate resistant prostate cancer; bispecific antibody

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Thakur, A.; Vaishampayan, U.; Lum, L.G. Immunotherapy and Immune Evasion in Prostate Cancer. Cancers 2013, 5, 569-590.

AMA Style

Thakur A, Vaishampayan U, Lum LG. Immunotherapy and Immune Evasion in Prostate Cancer. Cancers. 2013; 5(2):569-590.

Chicago/Turabian Style

Thakur, Archana; Vaishampayan, Ulka; Lum, Lawrence G. 2013. "Immunotherapy and Immune Evasion in Prostate Cancer." Cancers 5, no. 2: 569-590.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert